500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in
patients with plaque psoriasis, and other overlapping forms of psoriasis (such as plaque
psoriasis and psoriatic arthritis occurring together). The registry study will track the
behavior of the disease in response to other therapies, such as other biologic drugs. The
registry will also evaluate clinical outcomes, quality of life, and potential risks for
patients who may receive standard therapies for psoriasis.
Ages:18 and older
Inclusion Criteria: - Have a diagnosis of psoriasis - Are candidates for, or are currently receiving conventional systemic agents (eg, methotrexate, acitretin, cyclosporine or systemic psoralen drug in combination with Ultraviolet A light [PUVA]) or biologic therapy for psoriasis including those with chronic severe (extensive and/or disabling) plaque psoriasis who may be treated with infliximab - Ability to understand and sign an informed consent form - Are willing to participate in regular follow-up visits Exclusion Criteria: - Refuse to consent or are unwilling to respond to request for a long term information within the required time frame - Are participating or have already planned to participate in a clinical trial with non-marketed investigational agents or are participating in a Centocor-sponsored clinical trial with marketed agents
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Phase: Phase 4
Trial ID: NCT00508547
Not Accepting Healthy Volunteers